165 related articles for article (PubMed ID: 37149931)
1. Post COVID-19 condition after delta infection and omicron reinfection in children and adolescents.
Ertesvåg NU; Iversen A; Blomberg B; Özgümüş T; Rijal P; Fjelltveit EB; Cox RJ; Langeland N;
EBioMedicine; 2023 Jun; 92():104599. PubMed ID: 37149931
[TBL] [Abstract][Full Text] [Related]
2. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
[TBL] [Abstract][Full Text] [Related]
3. Symptom trajectories of post-COVID sequelae in patients with acute Delta or Omicron infection in Bergen, Norway.
Iversen A; Blomberg B; Haug K; Kittang B; Özgümüs T; Cox RJ; Langeland N
Front Public Health; 2024; 12():1320059. PubMed ID: 38504678
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
[TBL] [Abstract][Full Text] [Related]
5. Event rates and incidence of post-COVID-19 condition in hospitalised SARS-CoV-2 positive children and young people and controls across different pandemic waves: exposure-stratified prospective cohort study in Moscow (StopCOVID).
Pazukhina E; Rumyantsev M; Baimukhambetova D; Bondarenko E; Markina N; El-Taravi Y; Petrova P; Ezhova A; Andreeva M; Iakovleva E; Bobkova P; Pikuza M; Trefilova A; Abdeeva E; Galiautdinova A; Filippova Y; Bairashevskaia A; Zolotarev A; Bulanov N; DunnGalvin A; Chernyavskaya A; Kondrikova E; Kolotilina A; Gadetskaya S; Ivanova YV; Turina I; Eremeeva A; Fedorova LA; Comberiati P; Peroni DG; Nekliudov N; Genuneit J; Reyes LF; Brackel CLH; Mazankova L; Miroshina A; Samitova E; Borzakova S; Carson G; Sigfrid L; Scott JT; McFarland S; Greenhawt M; Buonsenso D; Semple MG; Warner JO; Olliaro P; Osmanov IM; Korsunskiy AA; Munblit D;
BMC Med; 2024 Feb; 22(1):48. PubMed ID: 38302974
[TBL] [Abstract][Full Text] [Related]
6. Antibody response against SARS-CoV-2 variants of concern in children infected with pre-Omicron variants: An observational cohort study.
Seery V; Raiden S; Russo C; Borda M; Herrera L; Uranga M; Varese A; Marcó Del Pont M; Chirino C; Erramuspe C; Álvarez LS; Lenoir M; Morales LD; Davenport C; Alarcón Flores A; Huespe Auchter S; Ruiz Y; Monsalvo L; Sastoque L; Gavazzi M; Mazzitelli I; Di Diego F; Longueira Y; Mazzitelli B; Sananez I; De Carli N; Biglione MM; Gómez Penedo JM; Ceballos A; Laufer N; Ferrero F; Geffner J; Arruvito L
EBioMedicine; 2022 Sep; 83():104230. PubMed ID: 35988465
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Symptoms Associated With SARS-CoV-2 Variants Among Children in Canada.
Sumner MW; Xie J; Zemek R; Winston K; Freire G; Burstein B; Kam A; Emsley J; Gravel J; Porter R; Sabhaney V; Mater A; Salvadori MI; Berthelot S; Beer D; Poonai N; Moffatt A; Wright B; Freedman SB;
JAMA Netw Open; 2023 Mar; 6(3):e232328. PubMed ID: 36892839
[TBL] [Abstract][Full Text] [Related]
8. Live-virus neutralization of the omicron variant in children and adults 14 months after SARS-CoV-2 wild-type infection.
Stich M; Benning L; Speer C; Garbade SF; Bartenschlager M; Kim H; Jeltsch K; Tabatabai J; Niesert M; Janda A; Renk H; Elling R; Hoffmann GF; Kräusslich HG; Müller B; Bartenschlager R; Tönshoff B
J Med Virol; 2023 Mar; 95(3):e28582. PubMed ID: 36794653
[TBL] [Abstract][Full Text] [Related]
9. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of post-COVID symptoms of the SARS-CoV-2 Delta and Omicron variants in children: a prospective study.
Yildirim Arslan S; Avcu G; Sahbudak Bal Z; Arslan A; Ozkinay FF; Kurugol Z
Eur J Pediatr; 2023 Oct; 182(10):4565-4571. PubMed ID: 37526704
[TBL] [Abstract][Full Text] [Related]
11. Severe Fatigue and Persistent Symptoms at 3 Months Following Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study.
Gottlieb M; Wang RC; Yu H; Spatz ES; Montoy JCC; Rodriguez RM; Chang AM; Elmore JG; Hannikainen PA; Hill M; Huebinger RM; Idris AH; Lin Z; Koo K; McDonald S; O'Laughlin KN; Plumb ID; Santangelo M; Saydah S; Willis M; Wisk LE; Venkatesh A; Stephens KA; Weinstein RA;
Clin Infect Dis; 2023 Jun; 76(11):1930-1941. PubMed ID: 36705268
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21.
Cohen C; Kleynhans J; von Gottberg A; McMorrow ML; Wolter N; Bhiman JN; Moyes J; du Plessis M; Carrim M; Buys A; Martinson NA; Kahn K; Tollman S; Lebina L; Wafawanaka F; du Toit JD; Gómez-Olivé FX; Dawood FS; Mkhencele T; Sun K; Viboud C; Tempia S;
Lancet Infect Dis; 2022 Jun; 22(6):821-834. PubMed ID: 35298900
[TBL] [Abstract][Full Text] [Related]
13. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
[TBL] [Abstract][Full Text] [Related]
15. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study.
Bager P; Wohlfahrt J; Bhatt S; Stegger M; Legarth R; Møller CH; Skov RL; Valentiner-Branth P; Voldstedlund M; Fischer TK; Simonsen L; Kirkby NS; Thomsen MK; Spiess K; Marving E; Larsen NB; Lillebaek T; Ullum H; Mølbak K; Krause TG;
Lancet Infect Dis; 2022 Jul; 22(7):967-976. PubMed ID: 35468331
[TBL] [Abstract][Full Text] [Related]
16. Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England.
Jeffery-Smith A; Rowland TAJ; Patel M; Whitaker H; Iyanger N; Williams SV; Giddings R; Thompson L; Zavala M; Aiano F; Ellis J; Lackenby A; Höschler K; Brown K; Ramsay ME; Gopal R; Chow JY; Ladhani SN; Zambon M
Lancet Healthy Longev; 2021 Dec; 2(12):e811-e819. PubMed ID: 34873592
[TBL] [Abstract][Full Text] [Related]
17. 3-year outcomes of discharged survivors of COVID-19 following the SARS-CoV-2 omicron (B.1.1.529) wave in 2022 in China: a longitudinal cohort study.
Zhang H; Huang C; Gu X; Wang Y; Li X; Liu M; Wang Q; Xu J; Wang Y; Dai H; Zhang D; Cao B
Lancet Respir Med; 2024 Jan; 12(1):55-66. PubMed ID: 38000376
[TBL] [Abstract][Full Text] [Related]
18. Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves.
Doll MK; Waghmare A; Heit A; Levenson Shakoor B; Kimball LE; Ozbek N; Blazevic RL; Mose L; Boonyaratanakornkit J; Stevens-Ayers TL; Cornell K; Sheppard BD; Hampson E; Sharmin F; Goodwin B; Dan JM; Archie T; O'Connor T; Heckerman D; Schmitz F; Boeckh M; Crotty S
JAMA Netw Open; 2023 Feb; 6(2):e231181. PubMed ID: 36853602
[TBL] [Abstract][Full Text] [Related]
19. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
[TBL] [Abstract][Full Text] [Related]
20. Lower prevalence of post-Covid-19 Condition following Omicron SARS-CoV-2 infection.
de Bruijn S; van Hoek AJ; Mutubuki EN; Knoop H; Slootweg J; Tulen AD; Franz E; van den Wijngaard CC; van der Maaden T
Heliyon; 2024 Apr; 10(7):e28941. PubMed ID: 38617937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
